Combined delivery of bone morphogenetic protein-2 and insulin-like growth factor-1 from nano-poly (γ-glutamic acid)/β-tricalcium phosphate-based calcium phosphate cement and its effect on bone regeneration in vitro

Abstract

In this study, nano-doped calcium phosphate cement delivery systems (poly (γ-glutamic acid)/β-tricalcium phosphate/calcium phosphate ceramics and nano (γ-glutamic acid)/β-tricalcium phosphate/calcium phosphate ceramic) were fabricated, and low doses (10 µg/g) of two growth factors, insulin-like growth factor-1 and bone morphogenetic protein-2, were encapsulated then sequentially released. We characterized the delivery systems using Fourier transform infrared spectroscopy and X-ray diffraction and measured washout resistance and compressive strength, and thus optimized the most appropriate proportioning of delivery systems for the two growth factors. One of the growth factors was absorbed by the nano-poly (γ-glutamic acid)/β-tricalcium phosphate, which was then mixed into the calcium phosphate ceramic solid phase to create a new solid phase calcium phosphate ceramic. Nano-poly (γ-glutamic acid)/β-tricalcium phosphate/calcium phosphate ceramic carriers were then prepared by blending the new calcium phosphate ceramic solid phase powder with a solution of the remaining growth factor. The effects of different release patterns (studying sequential behavior) of insulin-like growth factor-1 and bone morphogenetic protein-2 on osteogenic proliferation and differentiation of the MC3t3-E1 mouse osteoblast cell were investigated. This combinational delivery system provided a controlled release of the two growth factors, in which nano-doping significantly affected their release kinetics. The incorporation of dual growth factors could potentially stimulate bone healing and promoting bone ingrowth processes at a low dose.

Keywords

Dual delivery sequential release nano-doped calcium phosphate cement bone regeneration insulin-like growth factor-1 and bone morphogenetic protein-2

Get full access to this article

View all access options for this article.

References

Kim

Tabata

. Dual-controlled release system of drugs for bone regeneration. Adv Drug Deliver Rev 2015; 94: 28–40.

Hollinger

Alvarez

Ducheyne

et al.

Bone tissue engineering: growth factors and cytokines. Ref Module Mater Sci Mater Eng from Comprehen Biomater II 2017; 6: 20–53.

Kempen

Creemers

Alblas

et al.

Growth factor interactions in bone regeneration. Tissue Eng Part B Rev 2010; 16: 551–566.

Maus

Andereya

Gravius

et al.

BMP-2 incorporated in a tricalcium phosphate bone substitute enhances bone remodeling in sheep. J Biomater Appl 2008; 22: 559–576.

Miyazono

Maeda

Imamura

. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005; 16: 251–263.

Friedlaender

Perry

Cole

et al.

Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions: a prospective, randomized clinical trial comparing rhop-1 with fresh bone autograft. J Bone Joint Surg Am 2001; 83-A: S151–S151.

Luvizuto

Tangl

Zanoni

et al.

The effect of BMP-2 on the osteoconductive properties of β-tricalcium phosphate in rat calvaria defects. Biomaterials 2011; 32: 3855–3861.

Boden

Zdeblick

Sandhu

et al.

The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000; 25: 376–381.

Dolder

JVD

Ruijter

AJED

Spauwen

PHM

et al.

Observations on the effect of BMP-2 on rat bone marrow cells cultured on titanium substrates of different roughness. Biomaterials 2003; 24: 1853–1860.

10.

Wang

Israel

Kelly

et al.

Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors 1993; 9: 57–71.

11.

Carragee

Hurwitz

Weiner

. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011; 11: 471–491.

12.

Glassman

Howard

Dimar

et al.

Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases. Spine 2011; 36: 1849–1854.

13.

Taghavi

Lee

et al.

Bone morphogenetic protein binding peptide mechanism and enhancement of osteogenic protein-1 induced bone healing. Spine 2010; 35: 2049–2056.

14.

Lad

Bagley

Karikari

et al.

Cancer after spinal fusion: the role of bone morphogenetic protein. Neurosurg 2013; 73: 440–449.

15.

Nakamura

Tensho

Nakaya

et al.

Low dose fibroblast growth factor-2 (FGF-2) enhances bone morphogenetic protein-2 (BMP-2)-induced ectopic bone formation in mice. Bone 2005; 36: 399–407.

16.

Charles

Woodman

Ueno

et al.

Effects of low dose FGF-2 and BMP-2 on healing of calvarial defects in old mice. Exp Gerontol 2015; 64: 62–69.

17.

Gavenis

Heussen

Schmidt-Rohlfing

. Effects of low concentration BMP-7 on human osteoarthritic chondrocytes: comparison of different applications. J Biomater Appl 2012; 26: 845–859.

18.

Tsiridis

Upadhyay

Giannoudis

. Molecular aspects of fracture healing: which are the important molecules? Injury Int J Care Injured 2007; 38: S11–S25.

19.

Dimitriou

Tsiridis

Giannoudis

. Current concepts of molecular aspects of bone healing. Injury Int J Care Injured 2005; 36: 1392–1404.

20.

Liu

Wang

. Sequential delivery of BMP-7 and IGF-I to enhance the osteoinductive property of deproteinized bovine bone. Rsc Adv 2016; 6: 50322–50330.

21.

Kim

Kang

Krueger

et al.

Sequential delivery of BMP-2 and IGF-1 using a chitosan gel with gelatin microspheres enhances early osteoblastic differentiation. Acta Biomater 2012; 8: 1768–1777.

22.

Wang

Shang

et al.

Core-shell microspheres delivering FGF-2 and BMP-2 in different patterns for bone regeneration. J Mater Chem B 2015; 3: 1907–1920.

23.

Lei

Wang

et al.

Optimization of release pattern of FGF-2 and BMP-2 for osteogenic differentiation of low-population density hMSCs. J Biomed Mater Res A 2015; 103: 252–261.

24.

Nakamura

Tensho

Nakaya

et al.

Low dose fibroblast growth factor-2 (FGF-2) enhances bone morphogenetic protein-2 (BMP-2)-induced ectopic bone formation in mice. Bone 2005; 36: 399–407.

25.

Saikia

Bhattacharya

Bhuyan

et al.

Calcium phosphate ceramics as bone graft substitutes in filling bone tumor defects. Indian J Orthop 2008; 42: 169–172.

26.

Hesaraki

Nemati

. Cephalexin-loaded injectable macroporous calcium phosphate bone cement. J Biomed Mater Res 2009; 89B: 342–352.

27.

Chai

Hornez

Blanchemain

et al.

Antibacterial activation of hydroxyapatite (HA) with controlled porosity by different antibiotics. Biomol Eng 2007; 24: 510–514.

28.

Yang

Han

et al.

Incorporation of methotrexate in calcium phosphate cement: behavior and release in vitro and in vivo. Orthopedics 2009; 32: 27–27.

29.

Huang

Tian

Zhang

et al.

Strontium doping promotes bioactivity of rhBMP-2 upon calcium phosphate cement via elevated recognition and expression of BMPR-IA. Colloids Surf B Biointerf 2017; 159: 684–695.

30.

Liu

et al.

The promotion of bone tissue regeneration by BMP2 - derived peptide P24 - loaded calcium phosphate cement microspheres. Ceram Int 2016; 42: 3177–3189.

31.

Wang

Zhang

Zhu

et al.

Dynamic competitive adsorption of bone-related proteins on calcium phosphate ceramic particles with different phase composition and microstructure. J Biomed Mater Res B Appl Biomater 2013; 101B: 1069–1077.

32.

Ikawa

Kimura

Oumi

et al.

Amino acid containing amorphous calcium phosphates and the rapid transformation into apatite. J Mater Chem 2009; 19: 4906–4913.

33.

Stallmann

Roo

Faber

et al.

In vivo release of the antimicrobial peptide hLF1-11 from calcium phosphate cement. J Orthop Res 2008; 26: 531–538.

34.

Kazemzadeh-Narbat

Kindrachuk

Duan

et al.

Antimicrobial peptides on calcium phosphate-coated titanium for the prevention of implant-associated infections. Biomaterials 2010; 31: 9519–9526.

35.

Bose

Tarafder

. Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: a review. Acta Biomater 2012; 8: 1401–1421.

36.

Zhang

. Calcium phosphate/chitosan composite scaffolds for controlled in vitro antibiotic drug release. J Biomed Mater Res 2002; 62: 378–386.

37.

Zhang

. Effects of synergistic reinforcement and absorbable fiber strength on hydroxyapatite bone cement. J Biomed Mater Res 2005; 75A: 832–840.

38.

Tajima

Nishimoto

Kishi

et al.

Effects of added sodium alginate on mechanical strength of apatite cement. Dent Mater J 2004; 23: 329–334.

39.

Ishikawa

Miyamoto

Takechi

et al.

Non-decay type fast-setting calcium phosphate cement: hydroxyapatite putty containing an increased amount of sodium alginate. J Biomed Mater Res 1997; 36: 393–399.

40.

Chiang

Chen

et al.

Physicochemical properties and biocompatibility of chitosan oligosaccharide/gelatin/calcium phosphate hybrid cements. Mater Chem Phys 2010; 120: 282–288.

41.

Shie

Chen

Wang

et al.

Immersion behavior of gelatin-containing calcium phosphate cement. Acta Biomater 2008; 4: 646–655.

42.

Ginebra

Traykova

Planell

. Calcium phosphate cements as bone drug delivery systems: a review. J Control Release 2006; 113: 102–110.

43.

Mirtchi

Lemaitre

Terao

. Calcium phosphate cements: study of the β-tricalcium phosphate-monocalcium phosphate system. Biomaterials 1989; 10: 475–480.

44.

Mirtchi

Lemaitre

Hunting

. Calcium phosphate cements: action of setting regulators on the properties of the β-tricalcium phosphate-monocalcium phosphate cements. Biomaterials 1989; 10: 634–638.

45.

Shu

Shi

Feng

et al.

Design and in vitro evaluation of novel γ-PGA/hydroxyapatite nanocomposites for bone tissue engineering. J Mater Sci 2014; 49: 7742–7749.

46.

Shu

Shi

Feng

et al.

Poly (γ-glutamic acid)/beta-TCP nanocomposites via in situ copolymerization: preparation and characterization. J Biomater Appl 2016; 31: 102–102.

47.

Liu

. Recent advances towards the fabrication and biomedical applications of responsive polymeric assemblies and nanoparticle hybrid superstructures. Dalton Tr 2015; 44: 3904–3922.

48.

Das

Chan

PPY

Teo

et al.

In vitro cytotoxicity evaluation of biomedical nanoparticles and their extracts. J Biomed Mater Res A 2010; 93A: 337–346.

49.

Jingqun, Jiyan and Jiandong. Properties and cytocompatibility of anti - washout calcium phosphate cement by introducing locust Bean Gum. J Mater Sci Technol 2016; 32: 1021–1026.

50.

. Construction and properties of poly (lactic-co-glycolic acid)/calcium phosphate cement composite pellets with microspheres-in-pellet structure for bone repair. Ceram Int 2016; 42: 5587–5592.

51.

Miyazaki

Horibe

Antonucci

et al.

Polymeric calcium phosphate cements: setting reaction modifiers. Dent Mater 1993; 9: 46–50.

52.

dos Santos

De Oliveria

Rigo

et al.

Influence of polymeric additives on the mechanical properties of alpha-tricalcium phosphate cement. Bone 1999; 25: 9S–102S.

53.

Aryaei

Liu

Jayatissa

et al.

Cross-linked chitosan improves the mechanical properties of calcium phosphate-chitosan cement. Mat Sci Eng C 2015; 54: 14–19.

54.

Shen

Zhang

Yong

et al.

Sequential and sustained release of SDF-1 and BMP-2 from silk fibroin-nanohydroxyapatite scaffold for the enhancement of bone regeneration. Biomaterials 2016; 106: 205–216.

55.

Sar

Lin

et al.

Growth factors-loaded calcium phosphate/polymer hybrid coating with sequential release behavior prepared via electrochemical deposition method. Surf Coat Tech 2016; 303: 237–243.